vs
Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $11.9M, roughly 1.6× ASCENT INDUSTRIES CO.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -8.8%, a 7.9% gap on every dollar of revenue. On growth, ASCENT INDUSTRIES CO. posted the faster year-over-year revenue change (13.3% vs -25.7%). ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -34.9%).
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ACNT vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.9M | $18.7M |
| Net Profit | $-1.0M | $-154.0K |
| Gross Margin | 14.6% | — |
| Operating Margin | -21.0% | -6.9% |
| Net Margin | -8.8% | -0.8% |
| Revenue YoY | 13.3% | -25.7% |
| Net Profit YoY | -1.2% | 97.6% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.9M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $18.7M | $18.7M | ||
| Q1 25 | $24.7M | $50.9M | ||
| Q4 24 | $10.5M | $38.1M | ||
| Q3 24 | $20.9M | $33.4M | ||
| Q2 24 | $21.5M | $25.1M | ||
| Q1 24 | $28.0M | $41.5M |
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $6.3M | $-154.0K | ||
| Q1 25 | $-2.3M | $23.5M | ||
| Q4 24 | $-1.0M | $18.9M | ||
| Q3 24 | $-6.2M | $5.7M | ||
| Q2 24 | $-926.0K | $-6.5M | ||
| Q1 24 | $-5.5M | $13.8M |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | -21.0% | — | ||
| Q3 25 | -4.1% | — | ||
| Q2 25 | -14.4% | -6.9% | ||
| Q1 25 | -4.2% | 44.4% | ||
| Q4 24 | -25.4% | 46.4% | ||
| Q3 24 | -9.4% | 12.3% | ||
| Q2 24 | -8.6% | -33.7% | ||
| Q1 24 | -15.5% | 28.1% |
| Q4 25 | -8.8% | — | ||
| Q3 25 | -10.6% | — | ||
| Q2 25 | 33.7% | -0.8% | ||
| Q1 25 | -9.3% | 46.2% | ||
| Q4 24 | -9.8% | 49.6% | ||
| Q3 24 | -29.5% | 17.2% | ||
| Q2 24 | -4.3% | -26.0% | ||
| Q1 24 | -19.7% | 33.3% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.22 | — | ||
| Q2 25 | $0.65 | — | ||
| Q1 25 | $-0.23 | — | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.61 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.6M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.0M | $119.9M |
| Total Assets | $111.9M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | — | ||
| Q3 25 | $58.0M | — | ||
| Q2 25 | $60.5M | $49.0M | ||
| Q1 25 | $14.3M | $47.6M | ||
| Q4 24 | $16.1M | $38.1M | ||
| Q3 24 | $8.5M | $40.6M | ||
| Q2 24 | $3.6M | $43.2M | ||
| Q1 24 | $1.3M | $36.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $87.0M | — | ||
| Q3 25 | $87.1M | — | ||
| Q2 25 | $89.7M | $119.9M | ||
| Q1 25 | $91.2M | $25.0M | ||
| Q4 24 | $93.5M | $-456.0K | ||
| Q3 24 | $94.7M | $-23.5M | ||
| Q2 24 | $101.0M | $-31.2M | ||
| Q1 24 | $102.0M | $-31.7M |
| Q4 25 | $111.9M | — | ||
| Q3 25 | $119.9M | — | ||
| Q2 25 | $122.6M | $175.1M | ||
| Q1 25 | $152.5M | $98.5M | ||
| Q4 24 | $147.3M | $120.5M | ||
| Q3 24 | $148.6M | $139.0M | ||
| Q2 24 | $158.2M | $159.2M | ||
| Q1 24 | $161.0M | $184.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $266.0K | $-15.8M |
| Free Cash FlowOCF − Capex | $-196.0K | $-15.8M |
| FCF MarginFCF / Revenue | -1.7% | -84.6% |
| Capex IntensityCapex / Revenue | 3.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.1M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $266.0K | — | ||
| Q3 25 | $1.3M | — | ||
| Q2 25 | $-1.4M | $-15.8M | ||
| Q1 25 | $-700.0K | $-21.0M | ||
| Q4 24 | $8.8M | $-19.9M | ||
| Q3 24 | $3.4M | $-20.7M | ||
| Q2 24 | $2.2M | $-19.5M | ||
| Q1 24 | $263.0K | $-26.0M |
| Q4 25 | $-196.0K | — | ||
| Q3 25 | $695.0K | — | ||
| Q2 25 | $-1.5M | $-15.8M | ||
| Q1 25 | $-1.0M | $-21.2M | ||
| Q4 24 | $8.4M | $-20.0M | ||
| Q3 24 | $3.1M | $-20.7M | ||
| Q2 24 | $1.9M | $-19.6M | ||
| Q1 24 | $25.0K | $-26.2M |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | -8.3% | -84.6% | ||
| Q1 25 | -4.1% | -41.6% | ||
| Q4 24 | 80.6% | -52.5% | ||
| Q3 24 | 15.1% | -62.1% | ||
| Q2 24 | 9.1% | -78.2% | ||
| Q1 24 | 0.1% | -63.1% |
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 3.7% | 0.2% | ||
| Q3 24 | 1.3% | 0.1% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 0.9% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
